文献速递免疫规划慢病防控与筛查卫生政策与健康促进

HPV疫苗犹豫对日本宫颈癌的影响:一项建模研究

Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
PubMed 文献 · Lancet Public Health · 2020-02-10

日本2013年暂停HPV疫苗主动推荐后,接种率从超70%降至不足1%。该建模研究预测,疫苗犹豫危机将在1994-2007年出生队列中额外导致24600-27300例宫颈癌和5000-5700例死亡;若2020年恢复接种并补种,可预防其中14800-16200例和3000-3400例死亡。

要点

  • 2013-2019年疫苗危机使1994-2007年出生队列终生额外增加24600-27300例宫颈癌和5000-5700例死亡。
  • 2020年恢复70%常规接种并给错过队列50%补种,可预防14800-16200例和3000-3400例死亡。

核心结论

  • 迄今HPV疫苗危机估计将在日本导致约5000例宫颈癌死亡;若迅速恢复接种并扩大补种,其中许多死亡仍可预防。

研究设计与样本

  • 建模研究,使用Policy1-Cervix平台,适配日本HPV流行率、筛查实践与覆盖率及宫颈癌发病与死亡数据。
  • 评估1994-2007年出生队列终生宫颈癌病例与死亡,并模拟2020年起多种恢复场景及2013年起维持70%接种的反事实场景。

主要发现

  • 与2013年起维持约70%覆盖率相比,2013-2019年疫苗危机预测使1994-2007年出生队列终生额外增加24600-27300例宫颈癌和5000-5700例死亡。
  • 2020年恢复覆盖率(含错过队列补种)可预防其中14800-16200例宫颈癌和3000-3400例死亡。
  • 若2020年不恢复覆盖率,仅2020年12岁人群终生将额外增加3400-3800例和700-800例死亡。

关键数值与推荐

  • 恢复场景:常规覆盖率恢复至70%,错过队列(2020年13-20岁)补种覆盖率50%。
  • 反事实场景:2013年起12岁人群维持70%覆盖率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Funding for human papillomavirus (HPV) vaccination in Japan began in 2010 for girls aged 12-16 years, with three-dose coverage initially reaching more than 70%. On June 14, 2013, 2 months after formal inclusion in Japan's national immunisation programme, proactive recommendations for the HPV vaccine were suspended following reports of adverse events since found to be unrelated to vaccination, but which were extensively covered in the media. Vaccine coverage subsequently dropped to less than 1% and has remained this low to date. We aimed to quantify the impact of this vaccine hesitancy crisis, and the potential health gains if coverage can be restored. METHODS: In this modelling study, we used the Policy1-Cervix modelling platform. We adapted the model for Japan with use of data on HPV prevalence, screening practices and coverage, and cervical cancer incidence and mortality. We evaluated the expected number of cervical cancer cases and deaths over the lifetime of cohorts born from 1994 to 2007 in the context of the vaccine hesitancy crisis. We assessed a range of recovery scenarios from 2020 onwards, including a scenario in which routine coverage is restored to 70%, with 50% catch-up coverage for the missed cohorts (aged 13-20 years in 2020). To estimate the impact of the vaccine crisis to date, we also modelled a counterfactual scenario in which 70% coverage had been maintained in 12-year-olds from 2013 onwards. FINDINGS: The vaccine crisis from 2013 to 2019 is predicted to result in an additional 24 600-27 300 cases and 5000-5700 deaths over the lifetime of cohorts born between 1994 and 2007, compared with if coverage had remained at around 70% since 2013. However, restoration of coverage in 2020, including catch-up vaccination for missed cohorts, could prevent 14 800-16 200 of these cases and 3000-3400 of these deaths. If coverage is not restored in 2020, an additional 3400-3800 cases and 700-800 deaths will occur over the lifetime of individuals who are 12 years old in 2020 alone. If the crisis continues, 9300-10 800 preventable deaths due to cervical cancer will occur in the next 50 years (2020-69). INTERPRETATION: The HPV vaccine crisis to date is estimated to result in around 5000 deaths from cervical cancer in Japan. Many of these deaths could still be prevented if vaccination coverage with extended catch-up can be rapidly restored. FUNDING: National Health and Medical Research Council Australia Centre of Research Excellence in Cervical Cancer Control, Japan Society for the Promotion of Science.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Simms KT, Hanley SJB, Smith MA, et al. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020. PMID: 32057317. doi:10.1016/S2468-2667(20)30010-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。